Pure Global AI
NCT06205485Not yet recruiting

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

A Phase 3 Randomized Trial Of Neoadjuvant Chemotherapy, Excision And Observation Versus Chemoradiotherapy For Early Rectal Cancer
Canadian Cancer Trials GroupPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Rectal Cancer
Drug/Device/Intervention
Leucovorin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Canadian Cancer Trials Group
Timeline & enrollment
Phase
Phase 3
Start date
Mar 30, 2024
End date
Jun 30, 2030
Enrollment
250 participants
Primary outcome

Clinical response rate upon re-staging,Quality of Life defined using the LARS score

Summary

This study is being done to answer the following questions: Is the chance of rectal cancer
 responding the same if chemotherapy alone is given before limited surgery compared to
 chemotherapy and radiation therapy given together before limited surgery? If radiation
 therapy is not given, is quality of life better?

ICD-10 classifications
Malignant neoplasm of rectumCarcinoma in situ: RectumBenign neoplasm: RectumSecondary malignant neoplasm of large intestine and rectumCarcinoma in situ: Rectosigmoid junction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06205485
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06205485 through Pure Global AI's free database. This Phase 3 trial is sponsored by Canadian Cancer Trials Group and is currently Not yet recruiting. The study focuses on Rectal Cancer. Target enrollment is 250 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.